CD8A and neoplasm: Since ARAC’s effect is mainly mediated by CD8+ T cells, strategies to improve adaptive anti-tumor immunity and T cell activity, such as enhancing antigen presentation with an immune adjuvant or administering immune checkpoint inhibitors in combination, will be evaluated in our subsequent work.